EP Patent

EP3616695B1 — Ceftolozane/tazobactam for treating intrapulmonary infections

Assigned to Merck Sharp and Dohme LLC · Expires 2024-10-23 · 2y expired

What this patent protects

Patent listed against null.

Drugs covered by this patent

Patent Metadata

Patent number: EP3616695B1
Jurisdiction: EP
Classification: —
Expires: 2024-10-23
Drug substance claim: No
Drug product claim: No
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.